- Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market
- Maintained the pace of patient enrollment of the AR-105 global Phase 2 clinical study; on track for study completion mid-2019
- Phase 3 clinical study launch of AR-301 and initiation of AR-501 Phase 1/2a on pace to occur near year end 2018
- Strengthened patent estate with additional issued patents
PR Newswire
SAN JOSE, Calif., Nov. 13, 2018